Effect of pergolide treatment on insulin dysregulation in horses and ponies with pituitary pars intermedia dysfunction.
Authors: Galinelli, Bamford, Erdody, Mackenzie, Warnken, Harris, Sillence, Bailey
Journal: Equine veterinary journal
Summary
# Editorial Summary: Pergolide and Insulin Dysregulation in PPID Pituitary pars intermedia dysfunction (PPID) frequently coexists with insulin dysregulation (ID) in horses and ponies, and both conditions carry significant laminitis risk. Since dopamine may play a role in regulating insulin secretion, this randomised crossover trial examined whether pergolide mesylate—a dopamine receptor agonist used to manage PPID—could improve insulin sensitivity or reduce postprandial insulin responses in 16 horses and ponies (eight matched pairs with PPID+ID or ID-only). Over two 4-week treatment phases separated by washout, combined glucose-insulin tolerance testing and standardised meal testing (1.1 g/kg starch, 0.1 g/kg free sugars) quantified insulin sensitivity and postprandial responses before and after pergolide or control periods. Pergolide did not improve insulin sensitivity measured by tolerance testing in either group; however, animals with concurrent PPID and ID showed meaningful reductions in postprandial hyperinsulinaemia, with total insulin area under the curve falling by 25.4 min·mIU/mL and peak insulin concentration dropping by 100 μIU/mL. The ID-only group showed no response to pergolide. These findings suggest that dopamine agonism may selectively dampen meal-induced insulin surges in PPID horses with comorbid ID—potentially offering supplementary benefit beyond traditional PPID management—though tissue-level insulin sensitivity remains unaffected and requires alternative dietary or pharmaceutical strategies.
Read the full abstract on PubMed
Practical Takeaways
- •Pergolide does not improve underlying insulin sensitivity in dysregulated horses/ponies, so dietary management and exercise remain essential regardless of treatment
- •In PPID+ID cases, pergolide may help reduce problematic postprandial insulin spikes that trigger laminitis, but this benefit does not appear in ID-only horses
- •Do not expect pergolide monotherapy to resolve insulin dysregulation; it should be one component of a comprehensive metabolic management strategy including feed restriction and low-glycaemic diet
Key Findings
- •Pergolide treatment did not improve insulin sensitivity measured by CGIT in either PPID+ID or ID-only groups (p > 0.05)
- •Pergolide reduced postprandial insulin responses in PPID+ID animals: total AUC insulin decreased by 25.4 min·mIU/mL (p = 0.03) and peak insulin by 100 μIU/mL (p = 0.04)
- •Pergolide had no effect on postprandial insulin or glucose responses in the ID-only group
- •Dopamine agonist therapy may limit postprandial hyperinsulinaemia specifically in horses with concurrent PPID and insulin dysregulation